A possible explanation for the lack of tumor regression is that IL-7 by itself does not induce potent effector functions in CD8+ T cells (21) and would likely require a combination approach involving an immune-stimulatory factor to fully unlock its therapeutic potential. This evidence concerns the gene CD8A and neoplasm.